Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DCAPI1449 | Tiotropium Bromide Featured |
Tiotropium Bromide is a muscarinic acetylcholine receptor (mAChR M) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel. This stops signaling between neurons and leads to muscle relaxation.
More description
|
![]() |
DC11919 | Arimoclomol Featured |
A nontoxic heat shock protein (HSP) coinducer and potentiator of the heat shock response.
More description
|
![]() |
DC4184 | Vinorelbine Ditartrate Featured |
Vinorelbine (Navelbine) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
More description
|
![]() |
DCAPI1551 | Tacalcitol Featured |
Tacalcitol is a synthetic vitamin D3 analog. This compound has been shown to regulate calcium levels and induce nerve growth factor production in epidermal keratinocytes. Additionally, Tacalcitol has been noted to promotes normal bone development by regul
More description
|
![]() |
DC39024 | AT-527(Bemnifosbuvir hemisulfate) Featured |
AT-527(Bemnifosbuvir hemisulfate), a hemisulfate salt of AT-511, a guanosine nucleotide prodrug, is a potent and orally active HCV viral replication inhibitor. AT-527 is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity[1][2][3].Bemnifosbuvir hemisulfate has pan-genotypic antiviral activities that inhibits HCV genotype 1a (HCV GT1a), HCV GT1b, HCV GT2a, HCV GT3a, HCV GT4a, and HCV GT5a replication with EC50 values of 12.8 nM, 12.5 nM, 9.2 nM, 10.3 nM, 14.7 nM, and 28.5 nM, respectively[1].
In normal human airway epithelial cells, the concentration of Bemnifosbuvir hemisulfate required to inhibit replication of SARS-CoV-2 by EC90 is 0.47 μM, very similar to its EC90 against HCoV-229E, HCoV-OC43 and SARS-CoV in Huh-7 cells[2].When given orally to rats (500 mg/kg) and monkeys (30 mg/kg, 100 mg/kg or 300 mg/kg), Bemnifosbuvir hemisulfate preferentially delivers high levels of AT-9010 in the liver in vivo[1].
More description
|
![]() |
DC10611 | Trabectedin Featured |
Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo.
More description
|
![]() |
DC7429 | INCB 8761 Featured |
INCB8761(PF-4136309) is a potent, Selective, and orally bioavailable CCR2 antagonist.
More description
|
![]() |
DC10390 | TD139 Featured |
TD139 is a novel high-affinity inhibitor of the galectin-3 carbohydrate binding domain with a Kd of 14 nM.
More description
|
|
DC9475 | Ritonavir Featured |
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS,showed potent activity against COVID-19(SARS-COV-2) .
More description
|
![]() |
DCAPI1165 | Ribavirin (Copegus) Featured |
Ribavirin is a guanosine analog with antiviral properties against DNA and RNA viruses, including respiratory syncytial virus, hepatitis C, and influenza.
More description
|
![]() |
DCAPI1063 | Zanamivir (Relenza) Featured |
Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively.
More description
|
![]() |
DC9771 | ACU4429,ACU 4429,ACU-4429 Featured |
Emixustat hydrochloride strongly inhibits 11-cis-retinol production with IC50 values of 232 ± 3 nM.
More description
|
![]() |
DCAPI1010 | Peramivir Trihydrate Featured |
Peramivir, also known as BCX1812 and RWJ 270201, is an antiviral drug for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. Peramivir was approved to treat influenza infection in adults.
More description
|
![]() |
DC8471 | CGS 21680 hydrochloride Featured |
CGS 21680 hydrochloride is an A2A adenosine receptor agonist (Ki = 27 nM).
More description
|
![]() |
DC6904 | DAPAGLIFLOZIN Featured |
Dapagliflozin, also known as BMS-512148, is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered HbA1c by 0.6 versus placebo percentage points when added to metformin.
More description
|
![]() |
DC10440 | Namodenoson (CF-102) Featured |
CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.
target: A3 adenosine receptor agonist;
More description
|
![]() |
DC9915 | PF04995274,PF 04995274 Featured |
PF-04995274 is a 5-HT4 receptor partial agonist. It thought to act centrally as a pro-cognitive agent that being developed for the treatment of Alzheimer's disease (AD).
More description
|
![]() |
DC11485 | Tolcapone Featured |
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor.
More description
|
![]() |
DCAPI1497 | Cancidas Featured |
Caspofungin is a semi-synthetic analogue of pneumocandin B0 with improved water solubility, a significant limitation in the development of the echinocandin class as pharmaceuticals. Caspofungin acts by inhibition of the synthesis of β (1,3)-D-glucan, an e
More description
|
![]() |
DC10182 | Elacestrant (dihydrochloride) Featured |
Elacestrant dihydrochloride (RAD1901 dihydrochloride) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.
More description
|
![]() |
DCAPI1525 | 5-Azacytidine Featured |
5-Azacytidine is a potent growth inhibitor and a cytotoxic agent. 5-Azacytidine acts as a demethylating agent by inhibiting DNA methyltransferase (Dnmt), forming covalent adducts with cellular DNMT1 depleting enzyme activity. 5-Azacytidine also improves t
More description
|
![]() |
DC9011 | Mizoribine Featured |
Mizoribine(NSC 289637; HE 69; β-Bredinin) is an immunosuppressive agents (IC50=100 uM) that inhibit the proliferation of lymphocytes selectively, via inhibition of IMPDH.
More description
|
![]() |
DC10446 | (3R,4S,5S)-tert-butyl 3-Methoxy-5-Methyl-4-(MethylaMino)heptanoate hydroc hloride Featured |
Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist).
More description
|
![]() |
DC7114 | Dinaciclib (SCH727965) Featured |
Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively.
More description
|
![]() |
DC7486 | PX-478 2HCL Featured |
PX-478 is an inhibitor of HIF-1a with an IC50 of 20-30μM enhances radiosensitivity of prostate carcinoma cells.
More description
|
![]() |
DC10318 | Acelarin Featured |
Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.
More description
|
![]() |
DC2099 | cis-Diaminedichloroplatinum Featured |
Cisplatin is an inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.
More description
|
![]() |
DC9837 | Larotrectinib (LOXO-101 sulfate) Featured |
LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.
More description
|
![]() |
DC1101 | Ticagrelor (Brilinta,AZD6140) Featured |
Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.
More description
|
![]() |
DC7063 | Apremilast Featured |
Apremilast(CC10004) is a novel small molecule inhibitor of PDE4 with an IC50 value of 74 nM.
More description
|
![]() |